Who makes dacomitinib?
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer | Pfizer.
Is Dacomitinib FDA approved?
FDA approves dacomitinib for metastatic non-small cell lung cancer | FDA.
What is dacomitinib used for?
Dacomitinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Dacomitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
What is VIZIMPRO for?
Indication: VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).
Is Dacomitinib a chemotherapy drug?
Dacomitinib (Vizimpro) – Chemotherapy Drug Information | Chemocare.com.
What company makes afatinib?
Ridgefield, Conn., April 15, 2016, Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif ® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed …
How do you take afatinib?
Afatinib comes as a tablet to take by mouth. It is usually taken on an empty stomach once a day, at least 1 hour before or 2 hours after eating a meal or snack. Take afatinib at around the same time every day.
How much longer do you live with Verzenio?
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study.
How long can you stay on Verzenio?
Verzenio in early breast cancer Patients in both treatment arms were instructed to continue to receive hormone therapy for up to 5 to 10 years as recommended by their doctor. The primary endpoint of the study (still ongoing) is invasive disease-free survival (IDFS).
Where is afatinib manufactured?
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies.
What is the recommended Dacomitinib dose for use with food?
The recommended dacomitinib dose is 45 mg orally once daily with or without food. View full prescribing information for VIZIMPRO. FDA granted this application priority review and orphan drug designation.
Can you take Dacomitinib with Zimpro?
Drug Interactions: Concomitant use with a proton pump inhibitor (PPI) decreases dacomitinib concentrations, which may reduce VIZIMPRO efficacy. Avoid the concomitant use of PPIs with VIZIMPRO. As an alternative to PPIs, use locally-acting antacids or an H2-receptor antagonist.
What are the side effects of Dacomitinib?
The most common (>20%) adverse reactions of dacomitinib were diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus). The recommended dacomitinib dose is 45 mg orally once daily with or without food.
What is the prognosis of Dacomitinib-induced nephrotic syndrome?
The median progression-free survival, as determined by an independent review committee. was 14.7 and 9.2 months in the dacomitinib and gefitinib arms, respectively (hazard ratio 0.59; 95% CI: 0.47, 0.74; p<0.0001).